Rigel Pharmaceuticals Cost of Revenue 2011-2026 | RIGL

Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.

What is included in the cost of revenue

Cost Category	Examples
Production Costs	Materials, wages of production staff, depreciation of equipment
Service and Support	Customer service, user support, technical assistance
Delivery and Logistics	Packaging, delivery of goods to customers
Hosting and Infrastructure	Servers, cloud platforms (especially for IT and SaaS companies)
Content and Licenses	License purchases, production royalties (e.g., in streaming services)

Importance of the Metric

Helps to understand how costly the revenue-generating process is.
A high cost of revenue may indicate:
Poor cost control
Low operational efficiency
A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.

Annual Cost of Revenue Rigel Pharmaceuticals

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
19.6 M	18.6 M	7.11 M	1.75 M	1.08 M	895 K	906 K	287 K	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
19.6 M	287 K	6.29 M

Quarterly Cost of Revenue Rigel Pharmaceuticals

2025-Q3	2025-Q2	2025-Q1	2024-Q3	2024-Q2	2024-Q1	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
4.75 M	4.5 M	4.41 M	8.03 M	2.81 M	2.02 M	1.27 M	1.08 M	977 K	-	250 K	1.04 M	121 K	-	151 K	129 K	316 K	-	140 K	279 K	155 K	-	310 K	311 K	107 K	-	69 K	30 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
8.03 M	30 K	1.45 M

Cost of Revenue of other stocks in the Biotechnology industry

Issuer	Cost of Revenue	Price	% 24h	Market Cap	Country
Ascendis Pharma A/S ASND	3.52 M	$ 221.88	-0.87 %	$ 5 B	Danmark
MorphoSys AG MOR	32.2 M	-	2.43 %	$ 254 M	Germany
Pharming Group N.V. PHAR	20.6 M	$ 15.36	-0.71 %	$ 7.59 B	Niderland
I-Mab IMAB	27.2 M	-	-	$ 866 M	China
Midatech Pharma plc MTP	926 K	-	-18.52 %	$ 27.3 M	Britain
Aeterna Zentaris AEZS	90 K	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	40 K	-	-10.17 %	$ 12.2 K	USA
Acorda Therapeutics ACOR	15.3 M	-	-24.86 %	$ 820 K	USA
Albireo Pharma ALBO	1.36 M	-	-0.23 %	$ 916 M	USA
Acasti Pharma ACST	76 K	-	4.01 %	$ 150 M	Canada
Adverum Biotechnologies ADVM	100 K	-	-	$ 86.2 M	USA
Advaxis ADXS	13 K	-	-9.65 %	$ 45.9 M	USA
Axsome Therapeutics AXSM	47.5 M	$ 156.92	-1.23 %	$ 7.81 B	USA
Ayala Pharmaceuticals AYLA	602 K	-	-	$ 7.46 M	Israel
BioDelivery Sciences International BDSI	23.4 M	-	-4.8 %	$ 255 M	USA
BeiGene, Ltd. BGNE	70.7 M	-	0.49 %	$ 251 B	Cayman-islands
BioMarin Pharmaceutical BMRN	717 M	$ 54.13	-1.64 %	$ 10.4 B	USA
Compugen Ltd. CGEN	9.25 M	$ 2.09	-0.95 %	$ 195 M	Israel
Coherus BioSciences CHRS	13.8 M	$ 1.52	-5.59 %	$ 178 M	USA
CureVac N.V. CVAC	238 M	-	-	$ 867 M	Germany
Cellectis S.A. CLLS	31.4 M	$ 3.34	-4.02 %	$ 116 M	France